Granules

For ling long period , Granules is doing nothing....may I know at present what r d problems wid granules?...is there any FDA issues or any other prob.?..is it worthy of investment at this point???

 

https://rakesh-jhunjhunwala.in/what...s-it-qualify-as-a-potential-100-bagger-stock/

 

Granules suffered a minor setback in the last qr.which ended in March 2015 and its consolidated net profit declined by 5.2 per cent to Rs.22.40 crore from Rs.23.62 crore in the corresponding period of last year. Its consolidated net sales improved by 11.7 per cent. This is a keeper. It has good mgt. and good prospects being in the API business.

You should not worry too much or check on your stocks on a daily basis to worry about slippages. All one can do is analyze, take a fundamental decision and hold tight to a stock. My assumption is over a long term period Granules will be a good growth stock to have in your portfolio.

 

Thx...m also invested for long term...

 

A little info about granuels India . Granuels india already has 20 molecules and has generated a decent revenue . Right now they have bought a company auctus pharma for 102 crore . This company has around 17 molecules and already got a approval from USFDA (Probably they sold the company because of lacking of working capital) . The trick with this investment is , granuels india generate major revenue via exports from USA and Europe . Auctus pharma generates revenue only from domestic and is in loss . But after granuels india acquired this company , it would add value to granuels india since they can change the outlook of auctus pharma business by using their competitive advantage (Major Exports). Granuels India already have clients in USA and UK . With the new molecule , it would be easy for pushing the products of actus pharma . Also when europe gets out of the greece issue , the europe dollar would fly from the current rate which would add more revenue comparing to todays revenue(Dollar fluctuation) . With additional 17 molecules , granuels india can develop new molecules too . So there is potentially lots of upside with this company and valuation looks reasonable . It can be a game changer in next 5 - 8 years . In order to reduce the risk its always better to diversify with other companies so that your downside would be lower . ( This is not a recommendation , its just my analysis about the company regarding how it can add value to the investment )